Cargando…

Long-acting muscarinic antagonists for the treatment of asthma in children—a new kid in town

BACKGROUND: Asthma is the most prevalent chronic airway disease observed in children and adolescents, yet the variety of treatment options available for this age group is limited. With many factors influencing therapeutic efficacy including patient knowledge, adherence, and therapy choice as well as...

Descripción completa

Detalles Bibliográficos
Autor principal:	Hamelmann, Eckard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Medizin 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208794/ https://www.ncbi.nlm.nih.gov/pubmed/30416934 http://dx.doi.org/10.1007/s40629-018-0066-y

Ejemplares similares

Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium
por: Hamelmann, Eckard
Publicado: (2018)

Corrigendum to “Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium”
por: Hamelmann, Eckard
Publicado: (2019)

Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma
por: Aalbers, René, et al.
Publicado: (2017)

Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?
por: Busse, William W., et al.
Publicado: (2016)

Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?
por: Cazzola, Mario, et al.
Publicado: (2023)

Future perspectives of anticholinergics for the treatment of asthma in adults and children
por: Buhl, Roland, et al.
Publicado: (2019)

Novel long‐acting antagonists of muscarinic ACh receptors
por: Randáková, Alena, et al.
Publicado: (2018)

A comparison of tiotropium, long-acting β(2)-agonists and leukotriene receptor antagonists on lung function and exacerbations in paediatric patients with asthma
por: Vogelberg, Christian, et al.
Publicado: (2020)

Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD
por: D’Urzo, Anthony D, et al.
Publicado: (2018)

Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease
por: Ora, Josuel, et al.
Publicado: (2020)

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
por: Miravitlles, Marc, et al.
Publicado: (2018)

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
por: Yamada, Hideyasu, et al.
Publicado: (2018)

Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide
por: Price, David, et al.
Publicado: (2015)

Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium
por: Katsumata, Mineo, et al.
Publicado: (2022)

Addressing the risk domain in the long‐term management of pediatric asthma
por: Hamelmann, Eckard, et al.
Publicado: (2019)

Muscarinic Receptor Agonists and Antagonists
por: Broadley, Kenneth J., et al.
Publicado: (2001)

The role of long-acting muscarinic antagonist/long-acting β agonist fixed-dose combination treatment for chronic obstructive pulmonary disease in China: a narrative review
por: Zhou, Ji’an, et al.
Publicado: (2021)

The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review
por: Calzetta, Luigino, et al.
Publicado: (2022)

Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study
por: Lee, Su Yeon, et al.
Publicado: (2021)

Long-acting muscarinic antagonists vs. long-acting β (2) agonists in COPD exacerbations: a systematic review and meta-analysis
por: Maia, Israel Silva, et al.
Publicado: (2017)

A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β(2)-Agonist (LABA) Combinations in COPD
por: Sion, Katya Y. J., et al.
Publicado: (2017)

Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
por: Lee, Eung Gu, et al.
Publicado: (2023)

Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease
por: Hvisdas, Christopher
Publicado: (2021)

Asthma exacerbations and worsenings in patients aged 1–75 years with add-on tiotropium treatment
por: Mark FitzGerald, J., et al.
Publicado: (2020)

Investigating the Unbinding of Muscarinic Antagonists from the Muscarinic 3 Receptor
por: Buigues, Pedro J., et al.
Publicado: (2023)

New kid on the block: Artificial intelligence just moved into town
por: Osterwald, Ariane C., et al.
Publicado: (2023)

Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis
por: Ismaila, Afisi Segun, et al.
Publicado: (2015)

Kids, Difficult Asthma and Fungus
por: Bush, Andrew
Publicado: (2020)

Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit
por: Ulrik, Charlotte Suppli
Publicado: (2012)

Efficacy and Safety of Tiotropium in Children and Adolescents
por: Hamelmann, Eckard, et al.
Publicado: (2018)

Allergen reduction by nightly temperature controlled laminar airflow (TLA) decreases exacerbation rate in severe allergic asthma
por: Schauer, Uwe, et al.
Publicado: (2015)

Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease
por: Pleasants, Roy A.
Publicado: (2018)

Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease
por: Yuasa, Mizuki, et al.
Publicado: (2021)

Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists
por: Rebordosa, Cristina, et al.
Publicado: (2022)

Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium*
por: Colthorpe, Paul, et al.
Publicado: (2013)

Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan
por: Umeda, Akira, et al.
Publicado: (2023)

Muscarinic receptor signaling in the pathophysiology of asthma and COPD
por: Gosens, Reinoud, et al.
Publicado: (2006)

A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease
por: Muraki, Masato, et al.
Publicado: (2021)

Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease
por: Roberts, Melissa H., et al.
Publicado: (2019)

Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management
por: Kaplan, Alan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b26jmal9ghviq7esc22m2r622n